Assignee
EDISON PHARMACEUTICALS INC
US·17 granted patents·10 pending applications·387 citations·filing 2003–2016
Top patents by PatentIndex Score
27 records- 0198US9399612B2Treatment of pervasive developmental disorders with redox-active therapeuticsEDISON PHARMACEUTICALS INC·Filed 2015·Granted Jul 26, 2016·12 cites·11 claims
- 0298US8653144B2Treatment of pervasive developmental disorders with redox-active therapeuticsEDISON PHARMACEUTICALS INC·Filed 2012·Granted Feb 18, 2014·32 cites·31 claims
- 0398US7968746B24-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseasesEDISON PHARMACEUTICALS INC·Filed 2008·Granted Jun 28, 2011·46 cites·14 claims
- 0496US7432305B2Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkersEDISON PHARMACEUTICALS INC·Filed 2006·Granted Oct 7, 2008·60 cites·21 claims
- 0595US9169196B24-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseasesEDISON PHARMACEUTICALS INC·Filed 2013·Granted Oct 27, 2015·11 cites·24 claims
- 0695US7514461B2Chroman derivativesEDISON PHARMACEUTICALS INC·Filed 2004·Granted Apr 7, 2009·59 cites·6 claims
- 0795US7470798B27,8-bicycloalkyl-chroman derivativesEDISON PHARMACEUTICALS INC·Filed 2004·Granted Dec 30, 2008·60 cites·28 claims
- 0894US9370496B2Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinonesEDISON PHARMACEUTICALS INC·Filed 2013·Granted Jun 21, 2016·20 cites·16 claims
- 0990US8969420B2Treatment of pervasive developmental disorders with redox-active therapeuticsEDISON PHARMACEUTICALS INC·Filed 2014·Granted Mar 3, 2015·9 cites·22 claims
- 1089US7491312B2Identifying therapeutic compounds based on their physical-chemical propertiesEDISON PHARMACEUTICALS INC·Filed 2003·Granted Feb 17, 2009·47 cites·30 claims
- 1186US9296712B2Resorufin derivatives for treatment of oxidative stress disordersEDISON PHARMACEUTICALS INC·Filed 2013·Granted Mar 29, 2016·12 cites·19 claims
- 1285US9486435B2(Het)aryl-p-quinone derivatives for treatment of mitochondrial diseasesEDISON PHARMACEUTICALS INC·Filed 2014·Granted Nov 8, 2016·7 cites·17 claims
- 1383US9090576B22-substituted-p-quinone derivatives for treatment of oxidative stress diseasesEDISON PHARMACEUTICALS INC·Filed 2014·Granted Jul 28, 2015·3 cites·22 claims
- 1482US9629815B2Benzoquinone derivatives for treating oxidative stress disordersEDISON PHARMACEUTICALS INC·Filed 2013·Granted Apr 25, 2017·5 cites·17 claims
- 1581US9073873B22-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseasesEDISON PHARMACEUTICALS INC·Filed 2014·Granted Jul 7, 2015·4 cites·17 claims
- 1667US2014221674A1Process for the production of alpha-tocotrienol and derivativesEDISON PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 1766US9546132B24-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseasesEDISON PHARMACEUTICALS INC·Filed 2015·Granted Jan 17, 2017·0 cites·12 claims
- 1860US2009163529A1Identifying therapeutic compounds based on their physical-chemical propertiesEDISON PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 1960US2009162890A1Identifying therapeutic compounds based on their physical-chemical propertiesEDISON PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 2057US9567279B2Methods for oxidation of alpha tocotrienol in the presence of non-alpha tocotrienolsEDISON PHARMACEUTICALS INC·Filed 2015·Granted Feb 14, 2017·0 cites·14 claims
- 2157US2014249160A1Treatment of hearing and balance impairments with redox-active therapeuticsEDISON PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 2255US2014031433A1Formulations of tocotrienol quinones for the treatment of ophthalmic diseasesEDISON PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 2355US2014343166A1Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinonesEDISON PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 2452US2011142834A1Treatment of hearing and balance impairments using compounds having erythropoietin activityEDISON PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 2549US2017007553A1Methods for the prevention and treatment of cerebral ischemiaEDISON PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 2645US2016115141A1Carboxylic acid derivatives for treatment of oxidative stress disordersEDISON PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 2741US2014275045A1Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disordersEDISON PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when EDISON PHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →